Drug Profile
Research programme: PAK inhibitors - Cancer Research Technology/Pangaea Oncology
Latest Information Update: 09 Sep 2020
Price :
$50
*
At a glance
- Originator Cancer Research Technology; Pangaea Biotech
- Developer Cancer Research Technology; Pangaea Oncology
- Class
- Mechanism of Action P21 activated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 09 Sep 2020 Pangaea Biotech is now called Pangaea Oncology
- 28 Jun 2020 No recent reports of development identified for research development in Cancer in Spain
- 28 Jun 2020 No recent reports of development identified for research development in Cancer in United Kingdom